SG Americas Securities LLC Lowers Position in Certara, Inc. (NASDAQ:CERT)

SG Americas Securities LLC lessened its stake in Certara, Inc. (NASDAQ:CERT) by 65.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,839 shares of the company’s stock after selling 13,208 shares during the period. SG Americas Securities LLC’s holdings in Certara were worth $120,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of CERT. Raymond James & Associates boosted its position in Certara by 83.4% in the 1st quarter. Raymond James & Associates now owns 37,080 shares of the company’s stock worth $796,000 after purchasing an additional 16,861 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Certara by 1.1% in the 1st quarter. Bank of New York Mellon Corp now owns 384,913 shares of the company’s stock worth $8,268,000 after purchasing an additional 4,107 shares in the last quarter. HighTower Advisors LLC boosted its position in Certara by 71.6% in the 1st quarter. HighTower Advisors LLC now owns 19,847 shares of the company’s stock worth $440,000 after purchasing an additional 8,282 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Certara by 18.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,841 shares of the company’s stock worth $126,000 after purchasing an additional 905 shares in the last quarter. Finally, MetLife Investment Management LLC purchased a new stake in Certara in the 1st quarter worth approximately $111,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Stock Down 4.4 %

NASDAQ CERT opened at $16.21 on Friday. The business has a fifty day moving average price of $17.85 and a 200 day moving average price of $16.15. Certara, Inc. has a one year low of $11.81 and a one year high of $24.96. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.62 and a current ratio of 2.62. The company has a market cap of $2.60 billion, a P/E ratio of -46.31, a P/E/G ratio of 1.76 and a beta of 1.63.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Thursday, February 29th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.04). Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. The firm had revenue of $88.01 million during the quarter, compared to analyst estimates of $86.80 million. Research analysts anticipate that Certara, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on CERT. Barclays upped their price objective on Certara from $16.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. SVB Leerink assumed coverage on Certara in a research report on Monday, February 26th. They set a “market perform” rating and a $19.00 target price on the stock. Leerink Partnrs reiterated a “market perform” rating on shares of Certara in a research report on Monday, February 26th. JMP Securities assumed coverage on Certara in a research report on Thursday, April 4th. They set a “market perform” rating on the stock. Finally, Jefferies Financial Group increased their target price on Certara from $14.00 to $15.50 and gave the company a “hold” rating in a research report on Friday, March 1st. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $20.06.

Insider Activity at Certara

In other Certara news, SVP Richard M. Traynor sold 3,000 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares of the company’s stock, valued at approximately $3,123,432. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Certara news, insider Patrick F. Smith sold 14,427 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the completion of the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $844,033.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Richard M. Traynor sold 3,000 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares of the company’s stock, valued at $3,123,432. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,427 shares of company stock valued at $405,095. 2.60% of the stock is owned by insiders.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.